A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment with Elamipretide in Patients Hospitalized with Congestion due to Heart Failure
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Elamipretide (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms IDDEA-HF
- Sponsors Stealth BioTherapeutics
- 12 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Feb 2018.
- 12 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
- 10 Jun 2017 Biomarkers information updated